Developing transformative treatments for people with neuropsychiatric disorders
At Neuphoria Therapeutics, we are dedicated to pioneering breakthrough therapies that address the complex needs of individuals affected by neuropsychiatric disorders. By focusing on novel approaches and advancing scientific understanding, we aim to deliver medicines that offer lasting relief and hope for a brighter, healthier future.
A GROWING HEALTH CRISIS
Neuropsychiactric disorders affect nearly one in four U.S. adults each year, profoundly impacting our daily lives.
Available treatments such as Selective Serotonin Reuptake Inhibitors (SSRIs) and benzodiazepines, offer some benefits to patients but can sometimes result in more issues than they resolve.
We are pioneering a breakthrough therapy.
BNC210, a first-of-its-kind, well-tolerated experimental medication, is designed to restore balance in brain chemistry, providing rapid relief from neuropsychiatric symptoms without the common pitfalls of sedation, cognitive impairment, or addiction.
Emerging features and benefits
Broad-Spectrum Efficacy
Effective across a range of disorders.
Rapid Onset of Action
Using our fast-acting proprietary tablet formulation.
No Cognitive or Addiction Risks
Delivers relief without sedation, addiction potential, or mental fog.
New Mechanism of Action
Targets neurotransmitter balance in a novel way, filling critical gaps in current mental health treatments.
Contact us today
Discover how our groundbreaking technology is transforming mental health—contact us today to learn more.